Mecasermin

FDA approved

Mecasermin (Increlex) is recombinant human IGF-1, approved by the FDA in 2005 for children with severe primary IGF-1 deficiency, a rare condition where growth hormone cannot raise IGF-1 normally.

At a glance

Where it acts: Hormones & metabolism
Regulatory status: FDA approvedApproved by the U.S. FDA for at least one medical use.

Mechanism of Action

Mecasermin is identical to natural IGF-1. It binds the IGF-1 receptor, stimulating bone and cartilage growth and having insulin-like effects on glucose uptake, bypassing the growth hormone step that is defective in these children.

Typical Dosage (Research)

Prescription-only medicine. Dosing is set by a physician according to the FDA-approved label and the condition being treated.

Side Effects & Risks

Hypoglycemia (common), tonsil and adenoid enlargement, injection site fat changes, headache and ear problems.

Must be taken with a meal to avoid hypoglycemia. Risks include raised intracranial pressure, slipped capital femoral epiphysis and possible growth of existing tumors. Not a substitute for growth hormone.

Who Uses Mecasermin

Children with severe primary IGF-1 deficiency or growth hormone gene deletion with neutralizing antibodies.